Canaccord Genuity Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.
Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.